AR084439A1 - Plasmidos y vacunas recombinantes del virus sincicial respiratorio - Google Patents

Plasmidos y vacunas recombinantes del virus sincicial respiratorio

Info

Publication number
AR084439A1
AR084439A1 ARP110104823A ARP110104823A AR084439A1 AR 084439 A1 AR084439 A1 AR 084439A1 AR P110104823 A ARP110104823 A AR P110104823A AR P110104823 A ARP110104823 A AR P110104823A AR 084439 A1 AR084439 A1 AR 084439A1
Authority
AR
Argentina
Prior art keywords
virus
genes
mva
recombinant
rsv
Prior art date
Application number
ARP110104823A
Other languages
English (en)
Spanish (es)
Inventor
Rajesh Jain
Neeraj Aggarwal
Virender Kumar Vinayak
Pallavi Jaiswal
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of AR084439A1 publication Critical patent/AR084439A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP110104823A 2010-12-20 2011-12-20 Plasmidos y vacunas recombinantes del virus sincicial respiratorio AR084439A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3028DE2010 2010-12-20

Publications (1)

Publication Number Publication Date
AR084439A1 true AR084439A1 (es) 2013-05-15

Family

ID=45757038

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104823A AR084439A1 (es) 2010-12-20 2011-12-20 Plasmidos y vacunas recombinantes del virus sincicial respiratorio

Country Status (2)

Country Link
AR (1) AR084439A1 (fr)
WO (1) WO2012085936A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2869841T1 (sl) * 2012-07-05 2022-02-28 Glaxosmithkline Biologicals Sa Novi režimi za ojačitev odziva, ki vključujejo imunogene polipeptide, ki jih kodirajo polinukleotidi
WO2014005643A1 (fr) * 2012-07-05 2014-01-09 Okairos Ag Nouveaux régimes de primo-vaccination-rappel impliquant des polypeptides immunogènes codés par des polynucléotides
PT2879702T (pt) * 2012-08-01 2020-02-04 Bavarian Nordic As Vacina para o vírus sincicial respiratório (rsv) de vírus vaccinia modificado recombinante ankara (mva)
EA201891945A3 (ru) * 2012-08-01 2019-05-31 Бавариан Нордик А/С Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv)
US11571472B2 (en) 2014-06-13 2023-02-07 Glaxosmithkline Biologicals Sa Immunogenic combinations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100354425C (zh) * 1999-07-09 2007-12-12 美国政府健康及人类服务部 减毒的人－牛嵌合呼吸道合胞病毒疫苗的生产
WO2010075491A2 (fr) * 2008-12-24 2010-07-01 University Of Rochester Expression recombinante de sous-domaines porteurs d'épitopes neutralisants doués d'auto-repliement de l'attachement du virus respiratoire syncytial et protéines hybrides
AU2010250780A1 (en) 2009-05-18 2012-01-12 Panacea Biotec Ltd Universal influenza vaccine based on recombinant modified vaccinia Ankara virus (MVA)

Also Published As

Publication number Publication date
WO2012085936A2 (fr) 2012-06-28
WO2012085936A4 (fr) 2012-12-27
WO2012085936A3 (fr) 2012-10-11
WO2012085936A8 (fr) 2012-08-16

Similar Documents

Publication Publication Date Title
US8859257B2 (en) Vaccinia virus mutants containing the major genomic deletions of MVA
JP2010259446A5 (fr)
Meisinger-Henschel et al. Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice
US20160281066A1 (en) Mitogen-activated protein kinase-dependent recombinant vaccinia virus (md-rvv) and use thereof
JP2011004755A5 (fr)
MX2018012376A (es) Sistemas de replicón de arterivirus recombinantes y usos de estos.
Orubu et al. Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA
ES2623149T3 (es) Parvovirus atenuado vivo
JP2017502669A5 (fr)
BR112017000696B1 (pt) Polinucleotídeo isolado
Wennier et al. A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses
RU2019105695A (ru) Улучшенные способы получения библиотек полинуклеотидов в вирусах осповакцины/эукариотических клетках
CN118234850A (zh) 利用微rna来下调经修饰的安卡拉痘苗病毒(mva)的细胞毒性转基因的表达
CN104812894A (zh) 新型mva病毒及其用途
Zhu et al. The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes
Jordan et al. A deleted deletion site in a new vector strain and exceptional genomic stability of plaque-purified modified vaccinia Ankara (MVA)
Hsieh et al. Interaction of viruses with host cell molecular motors
Wong et al. Engineering recombinant poxviruses using a compact GFP–blasticidin resistance fusion gene for selection
Zhou et al. Establishment of an efficient and flexible genetic manipulation platform based on a fosmid library for rapid generation of recombinant pseudorabies virus
CN109706179A (zh) 稳定携带遗传标记的猪细小病毒感染性克隆系统及其构建方法和应用
CA2431349A1 (fr) Methode de production d'un virus recombinant
Liu et al. Comparison of different sites in recombinant Marek’s disease virus for the expression of green fluorescent protein
Neckermann et al. Transgene expression knock-down in recombinant Modified Vaccinia virus Ankara vectors improves genetic stability and sustained transgene maintenance across multiple passages
Agaoua et al. Synthetic Genome Shuffling of Poxviruses through Yeast for Next-Generation Oncolytic Platforms
Du et al. Development of recombinant rabies viruses vectors with Gaussia luciferase reporter based on Chinese vaccine strain CTN181

Legal Events

Date Code Title Description
FB Suspension of granting procedure